- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Forte Biosciences Reports Quarterly Earnings Miss
The biotech firm's Q1 results fell short of analyst expectations.
Apr. 1, 2026 at 2:50am
Got story updates? Submit your updates here. ›
Forte Biosciences (NASDAQ:FBRX), a clinical-stage biotech company focused on developing treatments for skin conditions, reported its first-quarter financial results on Tuesday. The company posted a loss of $1.45 per share, missing the consensus estimate of a $1.42 per share loss.
Why it matters
Forte Biosciences is working on innovative therapies to address serious dermatological conditions, so its quarterly performance is closely watched by investors and the industry. This earnings miss could raise concerns about the company's progress and the development of its lead product candidate, FB-401, a topical live biotherapeutic for atopic dermatitis.
The details
In its Q1 report, Forte Biosciences reported a loss of $1.45 per share, falling short of the $1.42 per share loss that analysts had expected. The company did not provide any additional details about its financial results or the status of its clinical programs.
- Forte Biosciences reported its Q1 2026 financial results on Tuesday, April 1, 2026.
The players
Forte Biosciences
A clinical-stage biotechnology company focused on developing innovative treatments to restore skin health by targeting the underlying biology of the skin barrier and microbiome.
The takeaway
This earnings miss could raise concerns about Forte Biosciences' progress and the development of its lead product candidate, FB-401, a topical live biotherapeutic for atopic dermatitis. Investors will be closely watching the company's future updates and clinical trial results to gauge the potential of its innovative skin health treatments.
